Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0269
FOCUS
|
Static and dynamic analysis with Next-Generation Sequencing.
|
Prof. Dr. Med Christof Hottenrott, MD, PhD.
|
Affiliation:Prof. Dr. Med (C H), Chirurgische Klinik St. Elisabethenkrankenhaus, Germany.
E-mail: info@gastricbreastcancer.com |
Abstract
Although static single-biopsy next-generation analysis has already identified novel cancer genes and druggable mutations for the development of new targeted drugs and molecular classifications, it has strong limitations to overcome therapeutic resistance and relapse.
Breakthrough translational strategies, including spatiotemporal genome analysis for intra-tumor heterogeneity with multi-regional next-generation sequencing (NGS) and cell-free DNA with NGS have been developed for overcoming primary and acquired drug resistance. Challenges and potential clinical utility are discussed.
(Citation: Gastric & Breast Cancer 2018; 13(1): 31-36)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
